Home › Compare › ATHJF vs JNJ

ATHJF vs JNJ: Dividend Comparison 2026

ATHJF yields 16666.67% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATHJF wins by $8601297707047409664.00M in total portfolio value
10 years
ATHJF
ATHJF
● Live price
16666.67%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8601297707047409664.00M
Annual income
$8,500,961,637,704,150,000,000,000.00
Full ATHJF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ATHJF vs JNJ

📍 ATHJF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATHJFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATHJF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ATHJF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATHJF
Annual income on $10K today (after 15% tax)
$1,416,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,225,817,392,048,527,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ATHJF beats the other by $7,225,817,392,048,527,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATHJF + JNJ for your $10,000?

ATHJF: 50%JNJ: 50%
100% JNJ50/50100% ATHJF
Portfolio after 10yr
$4300648853523704832.00M
Annual income
$4,250,480,818,852,075,000,000,000.00/yr
Blended yield
98.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ATHJF
No analyst data
Altman Z
-10.7
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATHJF buys
0
JNJ buys
0
No recent congressional trades found for ATHJF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATHJFJNJ
Forward yield16666.67% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$8601297707047409664.00M ✓$20.0K
Annual income after 10y$8,500,961,637,704,150,000,000,000.00 ✓$827.78
Total dividends collected$8594666089931243520.00M ✓$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ATHJF vs JNJ ($10,000, DRIP)

YearATHJF PortfolioATHJF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,677,367$1,666,666.67$10,676$355.77+$1.67M → ATHJF
2$263,066,849$261,272,066.46$11,407$389.39+$263.06M → ATHJF
3$38,576,943,838$38,295,462,310.00$12,198$426.53+$38576.93M → ATHJF
4$5,289,656,888,585$5,248,379,558,677.81$13,056$467.62+$5289656.88M → ATHJF
5$678,235,585,150,030$672,575,652,279,244.40$13,987$513.12+$678235585.14M → ATHJF
6$81,321,145,183,775,540$80,595,433,107,665,010.00$14,998$563.56+$81321145183.76M → ATHJF
7$9,118,299,079,523,715,000$9,031,285,454,177,076,000.00$16,098$619.52+$9118299079523.70M → ATHJF
8$956,159,646,381,740,000,000$946,403,066,366,649,700,000.00$17,295$681.69+$956159646381740.00M → ATHJF
9$93,772,027,423,605,150,000,000$92,748,936,601,976,690,000,000.00$18,599$750.82+$93772027423605152.00M → ATHJF
10$8,601,297,707,047,409,000,000,000$8,500,961,637,704,150,000,000,000.00$20,022$827.78+$8601297707047409664.00M → ATHJF

ATHJF vs JNJ: Complete Analysis 2026

ATHJF — Stock

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.

Full ATHJF Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ATHJF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATHJF vs SCHDATHJF vs JEPIATHJF vs OATHJF vs KOATHJF vs MAINATHJF vs ABBVATHJF vs MRKATHJF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.